After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Relay Therapeutics Inc is $689.64M. A total of 1.89 million shares were traded on the day, compared to an average of 1.92M shares.
In the most recent transaction, Rahmer Peter sold 15,724 shares of RLAY for 3.68 per share on Jul 29 ’25. After the transaction, the insider now owns 377,998 company shares. In a previous transaction on Jul 28 ’25, Rahmer Peter sold 1,359 shares at 3.74 per share. RLAY shares that the insider owns now total 393,722.
Among the insiders who sold shares, Catinazzo Thomas disposed of 18,380 shares on Jul 29 ’25 at a per-share price of $3.68. This resulted in the Chief Financial Officer holding 335,295 shares of RLAY after the transaction. In another insider transaction, Catinazzo Thomas sold 1,701 shares at $3.74 per share on Jul 28 ’25. Company shares held by the Chief Financial Officer now total 353,675.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RLAY has a high of $10.72 and a low of $1.77.
As of this writing, RLAY has an earnings estimate of -$0.42 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$0.32 per share and a lower estimate of -$0.51. The company reported an EPS of -$0.63 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RLAY’s latest balance sheet shows that the firm has $958.07M in Cash & Short Term Investments as of fiscal 2021. There were $22.90M in debt and $24.32M in liabilities at the time. Its Book Value Per Share was $3.88, while its Total Shareholder’s Equity was $897.81M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RLAY is Buy with a score of 4.54.
